Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?

Conclusion Upfront evaluation of kit mutation status may help us in delineating separate treatment strategies for potentially biologically different tumours and assessing the correct timing of surgery for this subset of GIST.

http://link.springer.com/10.1007/s12029-016-9835-3

Source: Journal of Gastrointestinal Cancer - May 23, 2016 Category: Cancer & Oncology Source Type: research